期刊文献+

外周血干细胞移植与高剂量化疗治疗卵巢癌 被引量:1

下载PDF
导出
摘要 卵巢癌是妇科致死率最高的肿瘤。其治疗方法主要为肿瘤细胞减灭术和术后化疗,有效的化疗可以及早防止卵巢癌复发,提高治愈率,缓解晚期卵巢癌的症状,延长生存期。传统化疗方法因存在耐药和毒性反应而有一定局限性。外周血干细胞移植(peripheral blood stem cell transplantation,PBSCT)支持下的高剂量化疗(high-dose chemotherapy,HDC),则能明显地减少毒副反应,缩短化疗周期,近年受到广泛关注。对这一方法治疗卵巢癌的研究进展作一综述。
作者 于海林 鹿欣
出处 《国际妇产科学杂志》 CAS 2008年第2期128-131,共4页 Journal of International Obstetrics and Gynecology
  • 相关文献

参考文献20

  • 1[1]Rangel LB,Agarwal R,D' Souza T,et al.Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas[J].Glin Cancer Res,2003,9(7):2567-2575.
  • 2[2]Lee S,Choi FJ,Jin C,et al.Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line[J].Gynecol Oncol,2005,97(1):26-34.
  • 3[3]Laport GG,Fleming GF,Wagganer S,et al.Progenitor cell mobilization A phase Ⅱ trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer[J].Bone Marrow Transplant,2001,27(7):677-681.
  • 4[4]Viret F,Bertucci F,Genre D,et al.Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma:a phase Ⅱ study[J].Bone Marrow Transplant,2002,30(12):879-884.
  • 5[5]Frickhofen N,Bordel WE,Opri F,et al.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness[J].Proc Natl Acad Sci U S A,2006,103 (30):11154-11159.
  • 6[6]Sehouli J,Stengel D,Oskay G,et al.A new therapeutical approach:topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum[J].Obstet G nac ol Res,2003,29 (3):123-131.
  • 7[7]Miller DS,Blessing JA,Lentz SS,et al.Phase Ⅱ evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma:a gynecologic oncology group study[J].Cancer,2003,98(8):1664-1669.
  • 8[8]Rodriguez M,Bose G.Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer[J].Gynecol Oncol,2001,83(2):257-262.
  • 9[9]Dcnchlag D,Watermann D,H(o)rig K,et al.Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients[J].Anticancer Res,2004,24(2):1267-1269.
  • 10[10]Tiersten A,Selleck M,Smith DH,et al.Phase Ⅰ/Ⅱ study of tandem cycles of high-dose chemotherapy followed by autologons hematopoietic stem cell support in women with advanced ovarian cancer[J],lnt J Gynecol Cancer,2006,16(1):57-64.

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部